CoChat

Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial

Open access
François, Bruno, Jafri, Hasan S, Chastre, Jean, Sánchez-García, Miguel, Eggimann, Philippe, Dequin, Pierre-François, Huberlant, Vincent, Viña Soria, Lucia, Boulain, Thierry, Bretonnière, Cédric, Pugin, Jérôme, Trenado, Josep, Hernandez Padilla, Ana Catalina, Ali, Omar, Shoemaker, Kathryn, Ren, Pin, Coenjaerts, Frank E, Ruzin, Alexey, Barraud, Olivier, Timbermont, Leen, Lammens, Christine, Pierre, Vadryn, Wu, Yuling, Vignaud, Julie, Colbert, Susan, Bellamy, Terramika, Esser, Mark T, Dubovsky, Filip, Bonten, Marc J, Goossens, Herman, Laterre, Pierre-François, Chochrad, Didier, Dive, Alain, Foret, Frédéric, Simon, Marc, Spapen, Herbert, Creteur, Jacques, Bouckaert, Yves, Biston, Patrick, Bourgeois, Marc, Novacek, Martin, Vymazal, Tomas, Svoboda, Petr, Pachl, Jan, Sramek, Vladimir, Hanauer, Michal, Hruby, Tomas, Balik, Martin, Suchy, Tomas, Lepape, Alain, Argaud, Laurent, Dailler, Frédéric, Desachy, Arnaud, Guitton, Christophe, Mercat, Alain, Meziani, Ferhat, Navellou, Jean-Christophe, Robert, Rene, Souweine, Bertrand, Tadie, Jean-Marc, Maamar, Adel, Annane, Djillali, Tamion, Fabienne, Gros, Antoine, Nseir, Saad, Schwebel, Carole, Francony, Gilles, Lefrant, Jean-Yves, Schneider, Francis, Gründling, Matthias, Motsch, Johann, Reill, Lorenz, Rolfes, Caroline, Welte, Tobias, Cornely, Oliver, Bloos, Frank, Deja, Maria, Schmidt, Katrin, Wappler, Frank, Meier-Hellmann, Andreas, Komnos, Apostolos, Bekos, Vasileios, Koulouras, Vasilios, Soultati, Ioanna, Baltopoulos, Georgios, Filntisis, Georgios, Zakynthinos, Epaminondas, Zakynthinos, Spyros, Pnevmatikos, Ioannis, Krémer, Ildikó, Szentkereszty, Zoltán, Sarkany, Agnes, Marjanek, Zsuzsa, Moura, Pedro, Pintado Delgado, Maria Consuelo, Montejo González, Juan Carlos, Ramirez, Paula, Torres Marti, Antonio, Valia, Juan Carlos, Lorente, Jose, Loza Vazquez, Ana, De Pablo Sanchez, Raúl, Escudero, Dolores, Ferrer Roca, Ricard, Pagani, Jean-Luc, Maggiorini, Marco · 2021 · The Lancet Infectious Diseases
Cited by 94

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

BACKGROUND Staphylococcus aureus remains a common cause of ventilator-associated pneumonia, with little change in incidence over the past 15 years. We aimed to evaluate the efficacy of suvratoxumab, a monoclonal antibody targeting the α toxin, in reducing the incidence of S aureus pneumonia in patients in the intensive care unit (ICU) who are on mechanical ventilation. METHODS We did a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial at 31 hospitals in Belgium, the Czech Republic, France, Germany, Greece, Hungary, Portugal, Spain, and Switzerland. Eligible patients were in the ICU, aged ≥18 years, were intubated and on mechanical ventilation, were positive for S aureus colonisation of the lower respiratory tract, as assessed by quantitative PCR (qPCR) analysis of endotracheal aspirate, and had not been diagnosed with new-onset pneumonia. Patients were excluded if they had confirmed or suspected acute ongoing staphylococcal disease; had received antibiotics for S aureus infection for more than 48 h within 72 h of randomisation; had a Clinical Pulmonary Infection Score of 6 or higher; had an acute physiology and chronic health evaluation II score of 25 or higher with a Glasgow coma scale (GCS) score of more than 5, or an acute physiology and chronic health evaluation II score of at least 30 with a GCS score of 5 or less; had a Sequential Organ Failure Assessment score of 9 or higher; or had active pulmonary disease that would impair the ability to diagnose pneumonia. Colonised patients were randomly assigned (1:1:1), by use of an interactive voice or web response system, to receive either a single intravenous infusion of suvratoxumab 2000 mg, suvratoxumab 5000 mg, or placebo. Randomisation was done in blocks of size four, stratified by country and by whether patients had received systemic antibiotics for S aureus infection. Patients, investigators, and study staff involved in the treatment or clinical evaluation of patients were masked to patient assignment. The primary efficacy endpoint was the incidence of S aureus pneumonia at 30 days, as determined by a masked independent endpoint adjudication committee, in all patients who received their assigned treatment (modified intention-to-treat [ITT] population). Primary safety endpoints were the incidence of treatment-emergent adverse events at 30 days, 90 days, and 190 days after treatment, and the incidence of treatment-emergent serious adverse events, adverse events of special interest, and new-onset chronic disease at 190 days after treatment. All primary safety endpoints were assessed in the modified ITT population. This trial is registered with ClinicalTrials.gov (NCT02296320) and the EudraCT database (2014-001097-34). FINDINGS Between Oct 10, 2014, and April 1, 2018, 767 patients were screened, of whom 213 patients with confirmed S aureus colonisation of the lower respiratory tract were randomly assigned to the suvratoxumab 2000 mg group (n=15), the suvratoxumab 5000 mg group (n=96), or the placebo group (n=102). Two patients in the placebo group did not receive treatment after randomisation because their clinical conditions changed and they no longer met the eligibility criteria for dosing. As adjudicated by the data monitoring committee at an interim analysis, the suvratoxumab 2000 mg group was discontinued on the basis of predefined pharmacokinetic criteria. At 30 days after treatment, 17 (18%) of 96 patients in the suvratoxumab 5000 mg group and 26 (26%) of 100 patients in the placebo group had developed S aureus pneumonia (relative risk reduction 31·9% [90% CI -7·5 to 56·8], p=0·17). The incidence of treatment-emergent adverse events at 30 days were similar between the suvratoxumab 5000 mg group (87 [91%]) and the placebo group (90 [90%]). The incidence of treatment-emergent serious adverse events at 30 days were also similar between the suvratoxumab 5000 mg group (36 [38%]) and the placebo group (32 [32%]). No significant difference in the incidence of treatment-emergent adverse events between the two groups at 90 days (89 [93%] in the suvratoxumab 5000 mg group vs 92 [92%] in the placebo group) and at 190 days (93 [94%] vs 93 [93%]) was observed. 40 (40%) patients in the placebo group and 50 (52%) in the suvratoxumab 5000 mg group had a serious adverse event at 190 days. In the suvratoxumab 5000 mg group, one (1%) patient reported at least one treatment-emergent serious adverse event related to treatment, two (2%) patients reported an adverse event of special interest, and two (2%) reported a new-onset chronic disease. INTERPRETATION In patients in the ICU receiving mechanical ventilation with qPCR-confirmed S aureus colonisation of the lower respiratory tract, the incidence of S aureus pneumonia at 30 days was not significantly lower following treatment with 5000 mg suvratoxumab than with placebo. Despite these negative results, monoclonal antibodies still represent one promising therapeutic option to reduce antibiotic consumption that require further exploration and studies. FUNDING AstraZeneca, with support from the Innovative Medicines Initiative Joint Undertaking.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(20)30995-6

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 94

Metadata

Authors
François, B., Jafri, H. S., Chastre, J., Sánchez-García, M., Eggimann, P., Dequin, P.-F., Huberlant, V., Viña Soria, L., Boulain, T., Bretonnière, C., Pugin, J., Trenado, J., Hernandez Padilla, A. C., Ali, O., Shoemaker, K., Ren, P., Coenjaerts, F. E., Ruzin, A., Barraud, O., Timbermont, L., Lammens, C., Pierre, V., Wu, Y., Vignaud, J., Colbert, S., Bellamy, T., Esser, M. T., Dubovsky, F., Bonten, M. J., Goossens, H., Laterre, P.-F., Chochrad, D., Dive, A., Foret, F., Simon, M., Spapen, H., Creteur, J., Bouckaert, Y., Biston, P., Bourgeois, M., Novacek, M., Vymazal, T., Svoboda, P., Pachl, J., Sramek, V., Hanauer, M., Hruby, T., Balik, M., Suchy, T., Lepape, A., Argaud, L., Dailler, F., Desachy, A., Guitton, C., Mercat, A., Meziani, F., Navellou, J.-C., Robert, R., Souweine, B., Tadie, J.-M., Maamar, A., Annane, D., Tamion, F., Gros, A., Nseir, S., Schwebel, C., Francony, G., Lefrant, J.-Y., Schneider, F., Gründling, M., Motsch, J., Reill, L., Rolfes, C., Welte, T., Cornely, O., Bloos, F., Deja, M., Schmidt, K., Wappler, F., Meier-Hellmann, A., Komnos, A., Bekos, V., Koulouras, V., Soultati, I., Baltopoulos, G., Filntisis, G., Zakynthinos, E., Zakynthinos, S., Pnevmatikos, I., Krémer, I., Szentkereszty, Z., Sarkany, A., Marjanek, Z., Moura, P., Pintado Delgado, M. C., Montejo González, J. C., Ramirez, P., Torres Marti, A., Valia, J. C., Lorente, J., Loza Vazquez, A., De Pablo Sanchez, R., Escudero, D., Ferrer Roca, R., Pagani, J.-L., & Maggiorini, M.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2021-09
Volume
21
Issue
9
Pages
1313-1323
ISSN
1473-3099 (ISSN-L)
OpenAlex
W3153513658
Cited by
94
References
5
FWCI
9.71
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. https://app.cochat.ai/papers/10.1016/s1473-3099(20)30995-6
The paper
François, B., Jafri, H. S., Chastre, J., Sánchez-García, M., Eggimann, P., Dequin, P.-F., Huberlant, V., Viña Soria, L., Boulain, T., Bretonnière, C., Pugin, J., Trenado, J., Hernandez Padilla, A. C., Ali, O., Shoemaker, K., Ren, P., Coenjaerts, F. E., Ruzin, A., Barraud, O., . . . Maggiorini, M. (2021). Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(20)30995-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.